Teva’s Generic Exclusivity For Pravachol Reinstated By Federal Judge
This article was originally published in The Pink Sheet Daily
Executive Summary
D.C. court reverses FDA’s determination that Teva’s 180-day exclusivity was triggered by an earlier patent dispute between Bristol and Apotex.